Longitudinal Metabolic Trajectories in Diabetes Prevention Program Participants Reveal Subgroups With Varying Micro- and Macrovascular Complication Risks.

Kobayashi E, Linden-Santangeli NJ, Chan N, Toomey CB, Mudaliar S, Temprosa M, Edelstein S, Goyal R, Rangamani P, Majithia AR, Diabetes Prevention Program Research Group

Impact of Parental or First-Degree Family History of Diabetes on Diabetes Incidence and Progression During Long-term Follow-up in the Diabetes Prevention Program Outcomes Study.

Dagogo-Jack S, Kazemi EJ, Doherty L, Srikanthan P, Echouffo-Tcheugui JB, Knowler WC, Kahn SE, Mudaliar S, Temprosa M, DPP Research Group

Super-Refractory Status Epilepticus Diagnosis, Management, and Prognostication: An International Survey Study.

Woodward MR, Brown JP, Kittner SJ, Badjatia N, Gilmore EJ, Johnson EL, Morris NA

Re-Considering the Indications for Unilateral Surgical Adrenalectomy in Primary Aldosteronism.

Brown JM, Vaidya A

Clinical Presentation and Rehabilitation Progression Following Hamstring Injury Assessed by BAMIC in Elite Track and Field.

Giakoumis M, Kelly S, Lee J, Stone B, Polglass G, Brown J, MacDonald B, Pollock N

Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium.

Blackmur JP, van der Mijn JCK, Warren AY, Browning L, Burgers F, Hirsch MS, Kapur P, Mehra R, Rao P, Signoretti S, Bex A, Stewart GD, van Montfoort ML, Jones JO, International Neoadjuvant Kidney Cancer Consortium

The butterfly effect: collateral damage and impacts of antimicrobial strategies on the oral microbiome.

Brown JL, Johnston W, Butcher MC, Burleigh M, Ramage G

Resistance of ERG24 sterol C-14 reductase to heterocyclic amine antifungals.

Arnold CJ, Chartrain L, Lawson DM, Brown JKM

Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study.

Nizam A, Nguyen CB, Li J, Zabor EC, Msaouel P, Jiang CY, Alhalabi O, Oh E, Davidsohn MP, Epstein IB, Bakaloudi DR, Talukder R, Jindal T, Taylor AK, Glover MJ, Khaki AR, Lemke E, Mabey H, Abuqayas B, Jang A, Brown JR, Evans ST, Pywell C, Basu A, Bilen MA, Barata PC, Zakharia Y, Milowsky MI, Kilari D, Hoimes CJ, Shah SA, Emamekhoo H, Davis NB, Gupta S, Grivas P, Bellmunt J, Campbell MT, Alva AS, Koshkin VS

Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trial.

Bevers LAH, Toledo G, Kisekka M, Kaudha E, Ahimbisibwe GM, Deprez I, Arumugan T, Variava E, Violari A, White I, Bbuye D, Nanduudu A, Mulwanyi E, Amuge P, Rutebarika DA, Kekitiinwa A, Kityo C, Musoke P, Archary M, Boles J, Thomason MJ, de Wildt SN, Giaquinto C, Colbers A, Burger DM, Buchanan AM, Chan MK, Jacobs TG, Turkova A, D3 TRIAL TEAM